HomeCompareAERI vs BTI

AERI vs BTI: Dividend Comparison 2026

AERI yields 13.11% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AERI wins by $9.7K in total portfolio value
10 years
AERI
AERI
● Live price
13.11%
Share price
$15.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.4K
Annual income
$2,963.65
Full AERI calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — AERI vs BTI

📍 AERI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAERIBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AERI + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AERI pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AERI
Annual income on $10K today (after 15% tax)
$1,114.75/yr
After 10yr DRIP, annual income (after tax)
$2,519.10/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, AERI beats the other by $150.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AERI + BTI for your $10,000?

AERI: 50%BTI: 50%
100% BTI50/50100% AERI
Portfolio after 10yr
$42.6K
Annual income
$2,875.15/yr
Blended yield
6.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AERI right now

AERI
Analyst Ratings
15
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$15.25
0.0% upside vs current
Range: $15.25 — $15.25
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AERI buys
0
BTI buys
0
No recent congressional trades found for AERI or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAERIBTI
Forward yield13.11%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$47.4K$37.7K
Annual income after 10y$2,963.65$2,786.64
Total dividends collected$21.1K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$15.25$40.00

Year-by-year: AERI vs BTI ($10,000, DRIP)

YearAERI PortfolioAERI Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$12,011$1,311.48$11,299$598.92+$712.00AERI
2$14,324$1,472.22$12,794$703.91+$1.5KAERI
3$16,968$1,640.86$14,518$829.07+$2.5KAERI
4$19,972$1,816.53$16,513$978.64+$3.5KAERI
5$23,369$1,998.27$18,827$1,157.84+$4.5KAERI
6$27,190$2,185.12$21,518$1,373.12+$5.7KAERI
7$31,469$2,376.08$24,657$1,632.46+$6.8KAERI
8$36,242$2,570.14$28,329$1,945.74+$7.9KAERI
9$41,545$2,766.31$32,637$2,325.33+$8.9KAERI
10$47,417$2,963.65$37,708$2,786.64+$9.7KAERI

AERI vs BTI: Complete Analysis 2026

AERIStock

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Full AERI Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this AERI vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AERI vs SCHDAERI vs JEPIAERI vs OAERI vs KOAERI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.